Press releases
-
-
-
-
-
Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets
-
Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
-
-
-
-
-
-
-
-
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
-
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
-
-
-
Internal link ProQR Announces Results for the Third Quarter of 2016
-
-
-
-
Internal link ProQR Announces Results for the Second Quarter of 2016
-
-
Internal link ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC
-
Internal link ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation